National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Cheson
B D
BD
National Cancer Institute, Bethesda, MD 20892-7436, USA.
Bennett
J M
JM
Grever
M
M
Kay
N
N
Keating
M J
MJ
O'Brien
S
S
Rai
K R
KR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002869:Chromosome Aberrations; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D003937:Diagnosis, Differential; D006801:Humans; D016130:Immunophenotyping; D007239:Infections / Q000209:etiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D018655:Lymphocyte Count; D009316:National Institutes of Health (U.S.); D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D018579:Patient Selection; D016896:Treatment Outcome; D014481:United States